About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
IP: María José Buzón Gómez Collaborators: Oriol Ruiz Isant, Laia Perez Lasarte Funding agency: Ministerio de Universidades Funding: 105936.74 Reference: FPU22/02404 Duration: 15/01/2024 - 14/01/2028
IP: Meritxell Genesca Ferrer Collaborators: María José Buzón Gómez, Joaquin Burgos Cibrian, Aleix Benítez Martínez Funding agency: Gilead Sciences, S.L.U. Funding: 49999.62 Reference: GLD23/00012 Duration: 01/03/2024 - 28/02/2026
IP: Susana Otero Romero Collaborators: Imane Boutitah Benyaich, Blanca Borras Bermejo, Anna Falcó Roget, Mar Tintore Subirana, Ana Zabalza de Torres, Jesus Trejo Zahinos, Enrique Rodríguez Zafra Funding agency: Instituto de Salud Carlos III Funding: 115000 Reference: PI23/01654 Duration: 01/01/2024 - 31/12/2026
IP: Elena Sulleiro Igual Collaborators: Pau Bosch Nicolau, Aroa Silgado Gimenez, Lidia Goterris Bonet Funding agency: Instituto de Salud Carlos III Funding: 108750 Reference: PI23/01942 Duration: 01/01/2024 - 31/12/2026
The study results show that the local presence of IL-1β promotes the development of myeloid cells with an immunosuppressive function.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
More than 50 healthcare professionals and community agents in Benguela receive specialized training to improve the detection and support of women with perinatal disorders.
